Tissue injury or reduced oxygen availability can activate angiogenic signaling within the affected retinal environment. Vascular endothelial growth factor, or VEGF, is identified in the overview as a key signal in this response. Its activity encourages vessel growth across weakened vascular boundaries, linking local tissue stress to the development of exudative lesions and subsequent visual disruption.
Vascular endothelial growth factor promotes the extension of new vessels from the choroid toward or beneath the retina after injury or ischemic stress. In arteriolar CNV, this signaling contributes not only to vessel growth but also to the formation of vessels prone to leakage. That leakage can produce fluid or blood accumulation and impair retinal organization.
The newly formed vessels are fragile and develop through weakened vascular boundaries, making them poorly suited to contain their contents. Fluid or blood can therefore escape into retinal tissues and create exudative lesions. These changes disturb retinal structure, which helps explain why visual symptoms may appear or worsen rapidly rather than progressing only gradually.
Leakage can impair vision by disturbing the retinal structure needed for normal visual function. Because the process may involve both fluid and blood, the resulting exudative changes can vary in extent and produce rapid visual changes. Monitoring the lesions is important because ongoing leakage signals continued activity that may threaten preservation of vision.
Clinical evaluation focuses on recognizing neovascular retinal disease and following changes in exudative lesions, leakage, and vision. Diagnosis establishes whether the retinal findings are consistent with this abnormal vascular response, while monitoring helps determine whether activity persists or changes. This information supports decisions about treatment and the need to preserve retinal function.
Intravitreal anti-VEGF therapy targets the angiogenic signaling that supports abnormal vessel growth and leakage. By inhibiting VEGF activity, treatment can reduce leakage from the affected vessels and help preserve vision. Its role is therefore directed at the active biological driver of the lesion rather than simply addressing the visible fluid or blood after it appears.